Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
09:15am, Wednesday, 06'th Aug 2025
Geron (GERN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights
07:01am, Wednesday, 06'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan
Geron Appoints Harout Semerjian as President and Chief Executive Officer
07:00am, Wednesday, 06'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the
Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025
08:00am, Monday, 28'th Jul 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and busi
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 18'th Jul 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 342,000
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Wednesday, 18'th Jun 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate o
Conservative Vision Of A Positive Future For Geron
09:57am, Tuesday, 03'rd Jun 2025
This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter s
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 19'th May 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN)
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws
LOS ANGELES, May 12, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers - GERN
01:39pm, Monday, 12'th May 2025
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain officers. T
The Gross Law Firm Notifies Shareholders of Geron Corporation(GERN) of a Class Action Lawsuit and an Upcoming Deadline
01:12pm, Monday, 12'th May 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).
